{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"FITWISE","nct_id":"NCT06518837","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=fitwise-nct06518837. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"FITWISE","arms":[{"description":"Tirzepatide will be administered subcutaneously in the stomach, upper arm, or thigh, rotating injection sites with each dose. Administer once weekly at any time of day, with or without meals. Start with an initial dosage of 2.5 mg. After 4 weeks, increase to 5 mg weekly. Further increases may be made in 2.5 mg increments after at least 4 weeks on the current dose, aiming for a target of 15 mg (i.e., 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg). Consider treatment tolerability when selecting the maintenance dose. If not tolerated, consider the next lower maintenance dose. Recommended maintenance doses are 5 mg, 10 mg, or 15 mg, with 5 mg as the lowest evaluable dose. The 2.5 mg dose is not a maintenance dose. The maximum allowed dosage is 15 mg once weekly.","label":"Tirzepatide","type":"EXPERIMENTAL"}],"collaborators":["Ludwig Institute for Cancer Research"],"completion_date":{"date":"2027-09-30","type":"ESTIMATED"},"conditions":["Hormone Receptor-Positive Breast Cancer","HER2-Negative Breast Cancer"],"enrollment":{"count":40,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Tirzepatide","otherNames":["LY3298176 (development code name)","Mounjaro (brand name in certain regions)","Zepbound (brand name in certain regions)"],"type":"DRUG"}],"last_update":"2026-01-21","lead_sponsor":"Rutgers, The State University of New Jersey","official_title":"FITWISE: Feasibility Study of Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-09-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Weight Loss Reduction with Tirzepatide during Adjuvant Treatment for HR+/Her2- Breast Cancer (Measured by Body Weight Reduction)","timeFrame":"Through study completion, total of two years."}],"references":[],"start_date":{"date":"2024-10-30","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer","url":"https://clinicaltrials.gov/study/NCT06518837"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/fitwise-nct06518837"}